Floatz logo

Irinotecan

BMS-986504

M.D. Anderson Cancer CenterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the BMS-986504 cohort.

Asset / SponsorPhaseRating
Eloxatin
M.D. Anderson Cancer Center
Phase 2CCC
FLUOROURACILUM
M.D. Anderson Cancer Center
Phase 2CCC
BMS-986504
M.D. Anderson Cancer Center
Phase 2CCC
Calcium folinate pentahydrate
M.D. Anderson Cancer Center
Phase 2CCC

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →